The Yeast Na+/H+ Exchanger Nhx1 Is an N-Linked Glycoprotein

TOPOLOGICAL IMPLICATIONS*

Karen M. Wells and Rajini RaoDagger

From the Department of Physiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

Received for publication, March 1, 2000, and in revised form, August 30, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Nhx1, the endosomal Na+/H+ exchanger of Saccharomyces cerevisiae represents the founding member of a newly emerging subfamily of intracellular Na+/H+ exchangers. These proteins share significantly greater sequence homology to one another than to members of the mammalian Na+/H+ exchanger (NHE) family encoding plasma membrane Na+/H+ exchangers. Members of both subtypes are predicted to share a common organization, with an N-terminal transporter domain of transmembrane helices followed by a C-terminal hydrophilic tail. In the present study, we show that Nhx1 is an asparagine-linked glycoprotein and that the sites of glycosylation map to two residues within the C-terminal stretch of the polypeptide. This is the first evidence, to date, for glycosylation of the C-terminal region of any known NHE isoform. Importantly, the mapping of N-linked glycosylation to the C-terminal domain of Nhx1 is indicative of an unexpected membrane topology, particularly with regard to the orientation of the tail region. Although one recent study demonstrated that certain epitopes in the C-terminal domain of NHE3 were accessible from the exoplasmic side of the plasma membrane (Biemesderfer, D., DeGray, B., and Aronson, P. S. (1998) J. Biol. Chem. 273, 12391-12396), numerous other studies implicate a cytosolic disposition for the hydrophilic C-terminal tail of plasma membrane NHE isoforms. Our analysis of the glycosylation of Nhx1 is strongly indicative of residence of at least some portion of the hydrophilic tail domain within the endosomal lumen. These findings imply that the organization of the tail domain may be more complex than previously assumed.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Mammalian Na+/H+ exchangers (NHE)1 are a ubiquitous family of transmembrane proteins that catalyze the antiport of Na+ and H+ at the plasma membrane. Under physiological conditions, NHE drive H+ out of the cell by coupling to the Na+ gradient, which is generated and maintained by the activity of the Na+/K+-ATPase. NHE are implicated in a variety of important physiological functions, including intracellular pH regulation, cell volume control, and Na+ homeostasis. Hydropathy analysis of the NHE1 isoform predicts that 10 to 12 transmembrane helices comprise the N terminus and that the C terminus constitutes a large cytoplasmic domain (1). This structure delineates function; the N-terminal domain, which is highly conserved among the various NHE isoforms, confers transport activity of the exchanger, whereas the considerably divergent C-terminal tail corresponds to a regulatory domain (2, 3). Numerous studies have shown that NHE isoforms can be post-translationally modified in a variety of ways. The cytosolic C-terminal tail domain modulates exchanger activity by becoming phosphorylated in response to extracellular signals like growth hormones (4) and through association with a variety of regulatory molecules, such as Ca2+/calmodulin (5). Some NHE isoforms are glycosylated in extracellular loops between transmembrane segments, although the functional significance of such modifications is unclear (6, 7).

Over the last several years, phenomenological evidence of intracellular Na+/H+ exchange has been documented in a variety of mammalian tissues (8-10), and in each case this activity colocalized with V-type H+-ATPase activity, suggesting an endosomal residence for Na+/H+ exchange. Our laboratory recently identified and cloned a Saccharomyces cerevisiae homologue of mammalian NHE, called Nhx1 (11), which represents the founding member of a unique and growing subfamily of intracellular Na+/H+ exchangers, including proteins identified in Schizosaccharomyces pombe, Caenorhabditis elegans, Arabidopsis thaliana, and humans. Nhx1 localizes to a late endosomal/prevacuolar compartment where it mediates intracellular sequestration of Na+ in a pH-dependent manner (11, 12), coupling Na+ movement to the proton gradient established by the vacuolar H+-ATPase (13, 34). Hydropathy analysis of Nhx1 reveals a domain structure similar to NHE isoforms, suggesting that the structure/function relationship for intracellular exchangers may be homologous to the plasma membrane-type antiporters. Here, we take a first step toward understanding how Nhx1 is regulated, specifically by investigating post-translational modification of the protein. We have determined that Nhx1 is an N-linked glycosylated protein and have shown that these glycosylations uniquely map to residues in the C-terminal hydrophilic tail portion of the exchanger. The presence of glycosylated asparagines in the C terminus predicts that at least some portion of the Nhx1 tail is exposed to the lumen of the late endosomal compartment. An earlier report demonstrated that epitopes within the NHE3 C-terminal tail were exposed to the exoplasmic side of the membrane (31), although there is no evidence for glycosylation of the tail region of NHE3 or any other NHE isoform. Taken together with the results of our study, these findings support an unpredicted topological arrangement for the C-terminal region of Na+/H+ exchangers that warrants further study.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Yeast Strains, Media, and Growth Assays-- R100, the Nhx1 null strain (Delta nhx1), is isogenic to W303 and has been described previously (11). R100 was the host strain unless otherwise indicated. sec7 and sec18 are temperature-sensitive strains isogenic to NY13 (14). The temperature-sensitive sec53 mutant was a gift of Peter Orlean. The wild-type strain W303 1A was a gift of Susan Michaelis. The synthetic minimal medium APG was used throughout and contained 10 mM arginine, 8 mM phosphoric acid, 2% glucose, 2 mM MgSO4, 1 mM KCl, 0.2 mM CaCl2, trace vitamins and minerals, pH ~6.7 (15). In some cases, NaCl was added, and the pH value was adjusted to 4.0 with acetic acid. For growth assays, 0.2-1-ml cultures, supplemented with NaCl as specified, were inoculated at an A600 value of 0.05 in a multi-well plate and incubated at 30 °C for 96 h, at which time A600 was measured.

Plasmids and Mutagenesis-- pRin73, a 2 µ plasmid harboring NHX1 tagged with a C-terminal triple hemagglutinin epitope (NHX1::HA), under control of its endogenous promoter, was created previously (12). Delta 512 is a C-terminal truncation of Nhx1 at residue 512, followed by the triple HA tag, and was created by a PCR-based method as follows (16). A 0.4-kilobase piece at the 3' end of NHX1 was amplified from pRin73 using a forward primer at the SpeI site (5'-CTGAAGTAGAACTAGTCTATAAGCCAC-3') and a reverse primer (5'-AACATCGTATGGGTAAAAGATGCGGCCGCCATTTATCGCCCTTGGAGCCTCTATATC-3'), which specified the junction of the truncated NHX1 gene with the HA tag sequence. The amplified product was used as a "megaprimer" in a second round of PCR using a reverse primer at the 3' untranslated region (5'-GGCACGAGCTCGTCTTCATCCATGACGGAAG-3') to give a 1.9-kilobase pair product. The latter was digested with SpeI and SacI and inserted into pRin72, a plasmid harboring the 5' end of the NHX1 gene (12), to give the final plasmid pKW403. Asparagine to aspartate point mutants of NHX1::HA were generated by a one-step PCR method (17) using pRin73 subclones as templates. For each PCR reaction, the point mutation (underlined) was introduced in one of the two oligonucleotides (forward and reverse) as follows: N121A/D, 5'-CTACTTTTTTAATGTTCTATTG-3' and 5'-GATGAAGC(T/C)AAAAGTAACCG-3'; N334D, 5'-CCTATTATGACATGTCAAGAAG-3' and 5'-CGTAATGTTTTAAAGTAATTCC-3'; N420D, 5'-GGAGAAGATATTTCTGTTCCC-3' and 5'-GGTTATGCCGCTCATAGATCTG-3'; N515D, 5'-TTATTGGACGGTAGTTCTATTCAG-3' and 5'-ATTTATCGCCCTTGGAGCCTCTATATC-3'; N550D, 5'-CCCAATGACATATCCACAAC-3' and 5'-GAGATTCTTGTTACTGCTG-3'; N563D, 5'-GAGGCCTTGATGAAACTGAGAATAC-3' and 5'-CAAAAGTATTACCACCAGTTG-3'. Double and triple point mutants were generated by consecutive rounds of the above PCR method, and all mutations were confirmed by sequencing.

Biochemical Methods-- Endo H and tunicamycin were from Roche Molecular Biochemicals and Sigma, respectively. For Endo H treatments, samples were pooled from sucrose density gradient fractions (30-46% w/w sucrose) enriched for Nhx1 (18). Briefly, cells from 600-ml overnight cultures (A600 = 0.5-1.0) were harvested and converted to spheroplasts using yeast lytic enzyme (10 mg/1600 OD units; ICN) for 45 min at 37 °C. Spheroplasts were suspended in 3-6 ml of lysis buffer (0.3 M sorbitol, 20 mM triethanolamine acetate, pH 7.2, 1 mM EDTA, and protease inhibitors) and homogenized with ~60 strokes of a Wheaton A Dounce homogenizer. The cleared lysate (~3 ml) was layered on top of and centrifuged through (2 h, 27,000 rpm, Beckman SW28 rotor, 4 °C) a 10-step sucrose gradient (3 ml each of 18-54% (w/w) in 4% increments). Fractions were collected from the top, pooled, and centrifuged for 1 h at 27,000 rpm; the final pellet was resuspended in ~50 µl of buffer (0.5 M sucrose, 10 mM MES/KOH, pH 6, 150 mM KCl) plus protease inhibitors. 30-50 µg of total protein was denatured for 10 min at 60 °C in 0.5% sodium dodecyl sulfate and 1% beta -mercaptoethanol, then diluted into 50 mM sodium citrate buffer, pH 5.5, and incubated either with or without Endo H at 37 °C for 18 h, as specified in legends to figures. Following treatment, samples were precipitated in 10% (v/v) trichloroacetic acid and centrifuged for 30 min at 4 °C, and pellets were resuspended in sample buffer prior to loading on gels.

For treatments with tunicamycin, 20-200-ml cultures were grown overnight at 30 °C to an A600 value of ~1, divided in two, and grown for two more hours following addition of tunicamycin (10 µg/ml final concentration) or an equal volume of carrier (5 µM NaOH). Aliquots (10-40 ml) were removed at indicated times, and total membranes were prepared by a glass bead method (18). Briefly, cells from each aliquot were harvested and resuspended in ~200 µl of bead buffer (10 mM Tris/HCl, pH 7.4, 0.3 M sorbitol, 0.1 M NaCl, 5 mM MgCl2) plus protease inhibitors. Acid-washed glass beads were added to the meniscus, and samples were vortexed 3 times for 1 min. Lysates were washed 3 times with 1 ml of bead buffer and, using a drawn-out pasteur pipette, removed to new tubes. Cleared lysates were centrifuged for 1 h at 45,000 rpm (Beckman Ti50 rotor, 4 °C), and final pellets were resuspended in ~30 µl of 20 mM K-Hepes, pH 7.4, plus protease inhibitors. Samples (30-100 µg) were diluted in sample buffer prior to loading on gels.

Protein concentrations were determined by the method of Lowry et al. (19) for total membrane preparations and by a modified Lowry method (20) for fractionation and pooled preparations. SDS-PAGE and Western blotting were as described previously (12). Antibodies used were mouse anti-HA monoclonal antibody, 12CA5 (Roche Molecular Biochemicals) at 1:5,000, and horseradish peroxidase-coupled sheep anti-mouse antibody (Amersham Pharmacia Biotech) at 1:10,000.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Nhx1 Is an N-Linked Glycosylated Protein-- Nhx1 exhibits a consistently multi-banded appearance upon gel electrophoresis, strongly suggestive of post-translational modification of the protein (12). To determine whether Nhx1 was N-glycosylated, a combination of in vivo and in vitro biochemical and genetic approaches were employed. Membrane fractions enriched for Nhx1 (see "Experimental Procedures") were treated with endoglycosidase H, an enzyme that cleaves high-mannose complex-type N-linked glycosylations (21, 22). As shown in Fig. 1A, Endo H treatment resulted in the disappearance of the upper collection of Nhx1 bands, indicative of a loss of N-linked glycosylation. To independently corroborate this observation, growing yeast cultures were treated with tunicamycin, an antibiotic that blocks all N-linked glycosylation of proteins by inhibiting the synthesis of dolichol diphosphate N-acetylglucosamine (23). As indicated in Fig. 1B, tunicamycin treatment directed the following time-dependent effects: (i) a gradual decline in the abundance of the Nhx1 protein; and (ii) a loss of the higher molecular weight bands, similar to the loss observed following Endo H treatment.



View larger version (43K):
[in this window]
[in a new window]
 
Fig. 1.   Nhx1 is an N-linked glycosylated protein. Western blots of HA-tagged Nhx1 are shown. A, Endo H treatment. Membranes (50 µg) pooled from sucrose gradients, as described under "Experimental Procedures," were from left to right, untreated, incubated in reaction buffer alone (Mock), or incubated in reaction buffer plus 1 milliunit of Endo H/µg of protein (Endo H). The positions of molecular weight markers are shown at the extreme left; the arrow to the right indicates disappearance of the upper set of bands. B, tunicamycin treatment. 10 µg/ml tunicamycin (Tu) was added to yeast cultures (W303/pRin73), and aliquots were removed at the indicated times. Total membranes were prepared, and 150 µg of protein was loaded per lane. The arrow to the right indicates the upper set of bands.

Biosynthesis of a glycosylated membrane protein begins in the endoplasmic reticulum, where cotranslational attachment of core glycosylation occurs, followed by movement to the Golgi, where there is further modification and maturation of glycosylation (24). In S. cerevisiae, a well defined set of temperature-sensitive sec mutants interrupt the biosynthetic pathway at discrete stages (14). We examined the expression of Nhx1 in the sec18, sec7, and sec6 mutants, which show temperature-dependent retention of protein in the endoplasmic reticulum, Golgi, and secretory vesicles, respectively. In the sec18 mutant, shift to the nonpermissive temperature resulted in a striking redistribution of Nhx1 bands from the higher to lower molecular weight (Fig. 2A), indicating that exit from the endoplasmic reticulum is required for the appearance of the higher molecular weight bands. Conversely, the upper bands became more intense following incubation at 37 °C in the sec7 mutant, indicative of increased modifications (Fig. 2B). There were no significant changes in Nhx1 mobility upon temperature shift in the sec6 mutant, suggesting that the modifications are completed in the Golgi or that Nhx1 does not traffic through secretory vesicles (not shown). To directly examine glycosylation status in vivo, Nhx1 was expressed in the sec53 mutant, which harbors a temperature-sensitive mutation in phosphomannomutase, an enzyme essential for the biosynthesis of both N- and O-linked glycosylations (25). Consistent with both Endo H and tunicamycin sensitivities, shifting Nhx1 from permissive (25 °C) to nonpermissive (37 °C) temperatures in sec53 resulted in loss of the upper bands on SDS-PAGE (Fig. 2C).



View larger version (95K):
[in this window]
[in a new window]
 
Fig. 2.   Expression of Nhx1 in temperature-sensitive sec mutant strains. Western blots of HA-tagged Nhx1 are shown; arrows on left indicate upper sets of bands. NHX1::HA (CEN, heat shock promoter) was transformed into sec18 (A) and sec7 (B) mutant strains. Cultures were grown to an A600 value of ~1, then divided, and allowed to grow for an additional 2 h at either permissive (25 °C) or nonpermissive (37 °C) temperatures. Total membranes were prepared, and 50 µg of protein was loaded in each lane. C, NHX1::HA (pRin73) was transformed into a sec53 mutant strain. The procedure was as above, except 70 µg of total protein was loaded in each lane.

Nhx1 Contains Six Consensus Sites for N-Linked Glycosylation-- Hydropathy analysis of Nhx1 (Fig. 3A) by the Kyte-Doolittle method (26) predicts multiple hydrophobic regions capable of spanning the lipid bilayer 10 to 13 times. Although less well defined, the hydropathic peaks numbered 6 and 7 share a high degree of identity with other NHE isoforms and are predicted to be involved in transport (27). Based on hydropathy analysis, transmembrane predictions, and models of plasma membrane NHE isoforms (3), we developed a working model for the membrane topology of Nhx1 (Fig. 3B). As drawn, the six consensus sites for N-linked glycosylation, -NX(S/T)- (28), are polarized into two groups; Asn-121, Asn-334, and Asn-420 are in loop regions of the N-terminal transmembrane domain and are predicted to face the lumen of the prevacuolar compartment, and Asn-515, Asn-550, and Asn-563 are in the C-terminal tail domain and are predicted to reside in the cytosol.



View larger version (36K):
[in this window]
[in a new window]
 
Fig. 3.   Predicted structure of Nhx1. A, hydropathy analysis of the primary sequence of Nhx1 using the Kyte-Doolittle algorithm (26). The asterisk indicates a possible transmembrane segment not included in the model shown in B. B, topological model of Nhx1, indicating strong consensus sites (-NX(S/T)-) for N-linked glycosylation (28) and sites of truncation and point mutation; numbers of transmembrane segments correspond to the numbered peaks on the hydropathy plot (A).

Nhx1 Is Glycosylated in the C-terminal Tail Domain-- Based on the preliminary topological model and the known sites of glycosylation in other NHE isoforms, we hypothesized that the likely site(s) of N-linked glycosylation were on the loops between transmembrane segments, namely at one or more of the residues Asn-121, Asn-334, and Asn-420. Each of these asparagines was individually replaced with aspartate, as described under "Experimental Procedures." Mutants N334D and N420D were as abundant as wild-type Nhx1; however mutant N121D was expressed at significantly lower levels. Regardless of expression levels, the aspartate point mutants conferred salt-tolerant growth that was indistinguishable from wild-type (Fig. 4A) and was clearly above the Delta nhx1 null strain (11). An alternate substitution, N121A, was generated; this mutant exhibited normal abundance levels, although salt tolerance was intermediate to wild-type and null mutant (not shown). The individual point mutants (N121A, N334D, and N420D) each exhibited a sensitivity to tunicamycin similar to that of wild-type (Fig. 4B), indicating a retention of N-linked glycosylation in vivo.



View larger version (36K):
[in this window]
[in a new window]
 
Fig. 4.   Effect of mutations in the N-terminal transporter domain of Nhx1. A, NaCl sensitivity of wild-type or mutant strains was assayed as described under "Experimental Procedures." Relative growth is the A600 value at a given NaCl concentration divided by A600 in the absence of NaCl, expressed as a percentage. Data points represent averages of two to four independent experiments. Western blots of HA-tagged Nhx1 are shown in B and C. B, tunicamycin-sensitivity. Lanes correspond to 2-h treatments with (+) or without (-) 10 µg/ml tunicamycin. Total membranes were loaded in the following amounts: upper panel, -Tu (50 µg) and +Tu (100 µg); lower panel, -Tu (100 µg) and +Tu (200 µg). C, Endo H treatment of the N-terminal triple loop mutant N121A/N334D/N420D. Endosomal membranes (30 µg) from sucrose density gradients were treated as described in the legend to Fig. 1, using 3.33 milliunits of Endo H/µg of protein.

It was possible that replacement of a glycosylated asparagine residue could lead to improper glycosylation at another, normally unmodified, consensus site for N-linked glycosylation. To address this concern, we created the triple loop mutant, N121A/N334D/N420D, and determined its glycosylation state. This triple mutant exhibited normal abundance and subcellular distribution but had decreased activity, as inferred from a reduction of salt tolerance to levels similar to the null strain (not shown). Most importantly, treatment with tunicamycin (Fig. 4B) and Endo H (Fig. 4C) resulted in a collapse of the upper collection of bands to a lower molecular weight, as in the single point mutants. Taken together, these results prove that mutation of all N-linked glycosylation consensus sites in the N-terminal domain does not prevent the normal glycosylation of Nhx1.

Next, we investigated whether the C-terminal tail harbored site(s) of N-linked glycosylation. There are three strong consensus sites for N-linked glycosylation at Asn-515, Asn-550, and Asn-563, as well as several weak sites. To test the hypothesis that some or all of these sites are normally glycosylated, we engineered two mutant Nhx1 constructs (see Fig. 3B), a C-terminal truncation at asparagine 512 (Delta 512), which deleted the three strong consensus sites for N-linked glycosylation in the tail region, and a triple mutant (N515D/N550D/N563D) in which aspartates replaced each of the three consensus asparagines. Fig. 5A clearly shows that unlike the wild-type control, the Delta 512 mutant was insensitive to Endo H treatment. As indicated in Fig. 5B, both Delta 512 and the triple mutant also appeared insensitive to tunicamycin treatment, strongly suggesting a loss of the site(s) of in vivo glycosylation. In contrast, the N334D mutant, used as a positive control because of its strong upper banding pattern (see Fig. 4B), showed a clear sensitivity to tunicamycin. Additionally, expression of either Delta 512 or the triple mutant in sec7 and sec18 strains resulted in no change in banding pattern upon shift to the nonpermissive temperature of 37 °C (Fig. 5C), an observation in stark contrast to that of the wild-type protein (see Fig. 2). It was possible that deletion of the C-terminal tail or mutation of the three asparagine residues resulted in polypeptides that were misfolded or abnormally localized and therefore not properly glycosylated. In earlier work, we have described the subcellular fractionation of yeast lysates on sucrose density gradients and shown colocalization of Nhx1 with endosomal markers (12). Here we show that the triple mutant was identical to wild-type Nhx1 in its distribution on sucrose density gradients (Fig. 6A), and in its tolerance to high salt (Fig. 6B), indicating that this protein was properly localized and fully functional. Distribution of the Delta 512 mutant showed some overlap with Golgi-containing fractions (12), suggesting a delay in trafficking out of the Golgi (Fig. 6A). Interestingly, Delta 512 had a sodium-sensitive phenotype intermediate to that of wild-type Nhx1 and Delta nhx1 (Fig. 6B), suggesting that the N-terminal transmembrane domain retains some transport function.



View larger version (62K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of C-terminal tail mutations on the glycosylation of Nhx1. Western blots of HA-tagged Nhx1 are shown. A, Endo H treatment. Endosomal membranes, pooled from sucrose gradient fractions, were incubated with (+) or without (-) 0.5 milliunits of Endo H/µg of protein; protein loaded was 30 µg for NHX1 and 20 µg for Delta 512. The arrow on the right indicates the disappearance of the upper set of wild-type bands. B, tunicamycin treatment was as in Fig. 1 legend; all lanes were loaded with 50 µg of protein. The arrow on the right indicates the disappearance of the upper set of bands. C, both Delta 512 and the C-terminal triple mutant (N515D/N550D/N563D) were transformed into sec7 and sec18 mutant strains as described in the legend to Fig. 2. Cultures were grown overnight, divided, and allowed to grow for an additional 2 h at either 25 or 37 °C. Total membranes were prepared, and 50 µg of protein was loaded in each lane.



View larger version (48K):
[in this window]
[in a new window]
 
Fig. 6.   Effect of C-terminal tail mutations on the subcellular localization and salt tolerance of Nhx1. A, Western blots of HA-tagged Nhx1. Equal protein was loaded in each lane as follows: 50 µg for Delta 512, 30 µg for Triple (N515D/N550D/N563D), and 50 µg for NHX1, from each of ten sucrose gradient fractions (18 to 54% sucrose; L = load). B, NaCl sensitivity of wild-type or mutant strains was assayed as described in the legend to Fig. 4.

Asn-515 and Asn-550 Are the Sites of N-Linked Glycosylation of Nhx1-- To map the precise site(s) of N-linked glycosylation, we created the single point mutants N515D, N550D, and N563D. Each mutant appeared fully functional, as evidenced by salt-tolerant growth (Fig. 7A). The abundance of each mutant was approximately equal to that of wild-type, but the banding pattern was upwardly shifted for the N515D and N550D mutants (Fig. 7B). Based on this observation, we constructed the double mutant N515D/N550D. Fig. 7C shows that although each of the three single point mutants appeared to retain tunicamycin sensitivity, the double mutant N515D/N550D, like the C-terminal triple mutant, was insensitive to tunicamycin treatment. The double aspartate mutant also showed an upward shift compared with wild-type, perhaps because of the substitution with charged residues. To test this hypothesis, we created a double mutant substituted with alanines rather than aspartates. As illustrated in Fig. 7D, mutant N515A/N550A does not show the mobility shift of the aspartate mutant and also exhibits an insensitivity to tunicamycin. Thus, the data indicate that Nhx1 is normally glycosylated at residues Asn-515 and Asn-550. We also verified a normal subcellular localization of the double mutant on sucrose density gradients (data not shown). These results confirmed that (i) both Asn-515 and Asn-550 were the sites of N-linked glycosylation; and (ii) none of the remaining consensus sites were glycosylated, as evidenced by the insensitivity of the double mutant to tunicamycin.



View larger version (32K):
[in this window]
[in a new window]
 
Fig. 7.   Nhx1 is glycosylated at residues Asn-515 and Asn-550. A, NaCl sensitivity of point mutants, as described in the legend to Fig. 4. Western blots of HA-tagged Nhx1 are shown in B-D. B, abundance of point mutants. Total membranes were prepared, and 50 µg of protein was loaded in each lane; duplicate lanes represent separate yeast transformants. C, tunicamycin treatment. Lanes correspond to 2-h treatments with (+) or without (-) 10 µg/ml tunicamycin; protein loaded was 50 µg (-Tu) and 100 µg (+Tu). Double is the double point mutant N515D/N550D. D, tunicamycin treatment, as in C; protein loaded was 100 µg (-Tu) and 150 µg (+Tu). DblA is the N515A/N550A mutant, and DblD is the N515D/N550D mutant.



    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

N-Linked Glycosylation of the Na+/H+ Exchanger Nhx1-- The present study shows that Nhx1, the yeast endosomal Na+/H+ exchanger, is post-translationally modified with N-linked glycosylations. Two independent experimental approaches, employing tunicamycin (in vivo) and Endo H (in vitro), resulted in similar effects; the uppermost collection of bands on Western blots of Nhx1 disappeared following treatment. The sensitivity of Nhx1 to Endo H indicates that the N-linked glycosylations are of the high mannose complex-type, created first by attachment of a core glycosylation in the endoplasmic reticulum and followed by maturation of that modification by enzymes in the Golgi. Temperature-sensitive blocks in vesicular traffic out of the endoplasmic reticulum (sec18) or Golgi (sec7) resulted in the expected loss or accrual of the higher molecular weight bands of Nhx1, respectively. These observations are consistent with those documented for other N-linked glycosylated membrane proteins in yeast (24, 29).

Using site-directed mutagenesis of the consensus sites for N-linked glycosylation, we have mapped Nhx1 glycosylation to the C-terminal hydrophilic tail domain, specifically to residues Asn-515 and Asn-550. Importantly, loss of N-linked glycosylation had no apparent effect on in vivo exchanger function, as evidenced by normal profiles of sodium-tolerant growth. Polypeptide expression levels and subcellular localization of nonglycosylated Nhx1 appeared similar to that of wild-type. Thus, the specific role of N-linked glycosylation of Nhx1 remains to be determined. Although the triple loop mutant was glycosylated normally, its sodium-sensitive growth was identical to the null strain, suggesting that this combination of point mutations (N121A/N334D/N420D) is deleterious for exchanger function. This observation may not be surprising, as each residue lies within the N-terminal transporter domain of the exchanger, and the single point mutant N121A exhibited a salt tolerance intermediate to wild-type and the null strain (data not shown).

Expression levels were drastically reduced only for the N121D mutant, which was not unexpected, given the predicted location of Asn-121 one to four amino acid residues inside the alpha -helical M4 transmembrane segment. Introduction of the negatively charged aspartate within the membrane may have led to destabilization and possibly increased degradation of the mutant polypeptide. It was noteworthy that the relative intensities and mobilities of the Nhx1 bands varied with the position(s) of substitution, as well as with the host strain and growth medium. For example, the mobilities of the bands in N334D was markedly changed, whereas N420D appeared very similar to wild-type. One explanation is that introduction of a negative charge at certain sites in the polypeptide affects migration of the protein on SDS-PAGE, perhaps in a way similar to that observed for other negatively charged groups such as phosphate. It is for this reason that we believe the double mutant N515D/N550D is shifted upward relative to wild-type Nhx1, and indeed this shift is ablated by mutation of each asparagine residue to alanine rather than aspartate (see Fig. 7D).

Topological Implications-- The mutational constructs of Nhx1 thus far created, and the analysis of these mutants in terms of glycosylation status, exchanger function, and localization, begins to elucidate the domain structure and topology of Nhx1, particularly as a model protein for the new subfamily of intracellular Na+/H+ exchangers. The demonstration of N-linked glycosylation in the C-terminal tail region of Nhx1 is novel for the following reasons: (i) to date, there is no evidence for glycosylation of any NHE isoform on its C-terminal tail domain; and (ii) the location of glycosylations implies an unusual topological disposition of the C-terminal tail of Nhx1. Thus far, only NHE1 has been shown to be N-linked glycosylated, and this site has been mapped to an extracellular loop between transmembrane domains M1 and M2 (6). Both NHE1 and NHE2 are O-linked glycosylated, each at sites between M1 and M2 (6, 7). There is no evidence, for any of the known NHE isoforms, that N-linked glycosylations exist on the C-terminal tail domain. Numerous functional studies suggest that the large hydrophilic C-terminal tail of NHE assumes a cytosolic orientation and constitutes a regulatory region of the exchanger. It is in fact this cytosolic domain that is implicated in pH "set point," calmodulin binding, protein kinase C-dependent phosphorylation, and volume sensitivity (27, 30). However, and of particular significance with regard to the present study, recent results indicate that some regions of the C-terminal domain of NHE3 assume an exoplasmic orientation. Two monoclonal antibodies directed against the C-terminal tail of NHE3 reacted with epitopes exposed at the extracellular surface (one epitope lies between residues 702 and 756, and the other epitope lies C-terminal to residue 756) (31). In contrast, during the preparation of this manuscript, a substituted cysteine-based topological analysis of the NHE1 isoform demonstrated that three residues (538, 561, and 794) in the C-terminal tail assumed the predicted cytosolic orientation (33). Our results, combined with these recent topological studies of NHE1 and NHE3, suggest either that there is considerable topological divergence in the C-terminal tail topology of various exchanger isoforms or that the organization of the tail domain is considerably complex.

The mapping of glycosylation sites in Nhx1 to the C-terminal domain strongly suggests that the hydrophilic tail, or some portion thereof, resides within the lumen of the prevacuolar compartment, rather than in the cytosol. Although this observation was unexpected in terms of homology to NHE isoforms, the physiological function(s) of intracellular Na+/H+ exchangers remains to be elucidated and thus may be consistent with some structural divergence from plasma membrane-type antiporters. A hallmark of the NHE family is the strong sequence conservation within the N-terminal transmembrane domain, which mediates transport function, whereas the hydrophilic C-terminal tail has diverged considerably, allowing for tissue- and cell-specific regulation (2, 3). A lumenal disposition of at least some portion of the putative regulatory domain of Nhx1 may be relevant for its proposed roles in endosomal volume control, Na+ sequestration, and pH homeostasis (12, 32).

A revised topological model for Nhx1 is essential, based on our new evidence that this protein is N-linked glycosylated on its hydrophilic C-terminal tail. Because we know very little about the physiological function or the orientation of the C terminus for this emerging subfamily of intracellular Na+/H+ exchangers, a variety of topology models are possible; one commonality must be that at least some portion of the C terminus (including residues Asn-515 and Asn-550) is lumenally accessible. The simplest model would assume a lumenal disposition for the entire C-terminal tail; the loss or gain of one transmembrane segment in Nhx1 would result in a lumenally oriented tail. Wakabayashi et al. (33) discovered in their recent study on NHE1 topology that a hydrophobic region, located between M11 and M12 of the original model, in fact constitutes an additional transmembrane segment. The homologous hydrophobic peak in Nhx1, indicated by an asterisk in Fig. 3A, could provide an unpredicted membrane-spanning segment that would dispose the C terminus to the lumen. An alternative model is that only certain portions of the Nhx1 C-terminal tail are accessible to the lumen; this would imply that part of the tail would have to traverse the lipid bilayer. Hydropathy analysis of Nhx1 and NHE isoforms indicates no putative membrane-spanning alpha -helices in the C-tail regions; hence, for NHE3, Biemesderfer et al. (31) suggest that region(s) of the C terminus may span the membrane as a beta -sheet. Such a scenario represents another plausible model that could explain our observations about Nhx1. To address these and other possibilities, we are currently pursuing a rigorous experimental dissection of the membrane topology of Nhx1.

The present study supports the idea that the modular domain structure of Nhx1 parallels exchanger function in a way similar to that of NHE isoforms. In particular, the large N-terminal transmembrane domain appears sufficient for Na+/H+ exchange activity; the truncation mutant Delta 512, in which 120 amino acids were deleted from the C-terminal end, can still confer salt tolerance, albeit at levels somewhat lower than wild-type. However, the C-terminal deletion also resulted in significantly increased abundance of the polypeptide, as well as a partial shift in subcellular localization into Golgi-containing fractions of the sucrose density gradient. It is possible that slower trafficking of the truncated protein out of the Golgi also delays its proteolytic turnover, accounting for increased abundance.

It is interesting that even in the absence of N-linked glycosylation, Nhx1 retains some multi-banded appearance upon gel electrophoresis. Expression of Nhx1 in the sec53 mutant, which blocks all O-linked and N-linked glycosylations, retains some measure of multi-banded character, as well. These data suggest the existence of additional post-translational modifications of Nhx1. In particular, the sequence of the first predicted transmembrane helix reveals features reflective of a signal peptide, and we have preliminary evidence for an N-terminal cleavage event. Additionally, there are numerous consensus sites for protein kinase C- and casein kinase II-dependent phosphorylation distributed throughout the polypeptide.

In conclusion, our finding that Nhx1 is N-linked glycosylated at two residues in its hydrophilic C-terminal tail domain makes an experimental dissection of membrane topology imperative; this should contribute greatly to future studies on molecular structure and function. The observation that a C-terminally truncated mutant and the N515D/N550D double mutant retain heterogeneity on SDS-PAGE Western blots paves the way for further characterization of post-translational modification(s) and of how this intracellular exchanger might be regulated.


    FOOTNOTES

* This work was supported by an American Health Association Maryland Affiliate post-doctoral fellowship award (to K. W.) and by Grants GM52414 and DK54214 from the National Institutes of Health (to R. R.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Dept. of Physiology, The Johns Hopkins University School of Medicine, 725 N. Wolfe St., Baltimore, MD 21205. Tel.: 410-955-4732; Fax: 410-955-0461; E-mail: rrao@jhmi.edu.


    ABBREVIATIONS

The abbreviations used are: NHE, Na+/H+ exchangers; HA, hemagglutinin; PCR, polymerase chain reaction; Endo H, endoglycosidase H; PAGE, polyacrylamide gel electrophoresis; MES, 4-morpholineethanesulfonic acid.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Sardet, C., Franchi, A., and Pouyssegur, J. (1989) Cell 56, 271-280[Medline] [Order article via Infotrieve]
2. Wakabayashi, S., Fafournoux, P., Sardet, C., and Pouyssegur, J. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 2424-2428[Abstract]
3. Orlowski, J., and Grinstein, S. (1997) J. Biol. Chem. 272, 22373-22376[Free Full Text]
4. Sardet, C., Counillon, L., Franchi, A., and Pouyssegur, J. (1990) Science 247, 723-726[Medline] [Order article via Infotrieve]
5. Bertrand, B., Wakabayashi, S., Ikeda, T., Pouyssegur, J., and Shigekawa, M. (1994) J. Biol. Chem. 269, 13703-13709[Abstract/Free Full Text]
6. Counillon, L., Pouyssegur, J., and Reitmeier, R. A. F. (1994) Biochemistry 33, 10463-10469[Medline] [Order article via Infotrieve]
7. Tse, C. M., Levine, S. A., Yun, C. H. C., Khurana, S., and Donowitz, M. (1994) Biochemistry 33, 12954-12961[Medline] [Order article via Infotrieve]
8. Hilden, S. A., Ghoshroy, K. B., and Madias, N. E. (1990) Am. J. Physiol. 258, F1311-F1319[Abstract/Free Full Text]
9. Van Dyke, R. W. (1995) Am. J. Physiol. 269, C943-C954[Abstract/Free Full Text]
10. Thevenod, A. F. (1996) J. Membr. Biol. 152, 195-205[CrossRef][Medline] [Order article via Infotrieve]
11. Nass, R., Cunningham, K. W., and Rao, R. (1997) J. Biol. Chem. 272, 26145-26152[Abstract/Free Full Text]
12. Nass, R., and Rao, R. (1998) J. Biol. Chem. 273, 21054-21060[Abstract/Free Full Text]
13. Gaxiola, R. A., Rao, R., Sherman, A., Grisafi, P., Alper, S. L., and Fink, G. R. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 1480-1485[Abstract/Free Full Text]
14. Novick, P., and Schekman, R. (1979) Proc. Natl. Acad. Sci. U. S. A. 76, 1858-1862[Abstract]
15. Rodriguez-Navaro, A., and Ramos, J. (1984) J. Bacteriol. 159, 940-945[Medline] [Order article via Infotrieve]
16. Sarker, G., and Sommer, S. S. (1990) Biotechniques 8, 404-407[Medline] [Order article via Infotrieve]
17. Fisher, C. L., and Pei, G. K. (1997) Biotechniques 23, 570-574[Medline] [Order article via Infotrieve]
18. Sorin, A., Rosas, G., and Rao, R. (1997) J. Biol. Chem. 272, 9895-9901[Abstract/Free Full Text]
19. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) J. Biol. Chem. 193, 265-275[Free Full Text]
20. Bensadoun, A., and Weinstein, D. (1976) Anal. Biochem. 70, 241-250[Medline] [Order article via Infotrieve]
21. Kobata, A. (1979) Anal. Biochem. 100, 1-14[Medline] [Order article via Infotrieve]
22. Trimble, R. B., and Maley, F. (1984) Anal. Biochem. 141, 515-522[Medline] [Order article via Infotrieve]
23. Duskin, D., and Mahoney, W. C. (1982) J. Biol. Chem. 257, 3105-3109[Abstract/Free Full Text]
24. Herscovics, A., and Orlean, P. (1993) FASEB. J. 7, 540-550[Abstract/Free Full Text]
25. Kepes, F., and Schekman, R. (1988) J. Biol. Chem. 263, 9155-9161[Abstract/Free Full Text]
26. Kyte, J., and Doolittle, R. F. (1982) J. Mol. Biol. 157, 105-132[Medline] [Order article via Infotrieve]
27. Wakabayashi, S., Shigekawa, M., and Pouyssegur, J. (1997) Physiol. Rev. 77, 51-74[Abstract/Free Full Text]
28. Marshall, R. D. (1972) Annu. Rev. Biochem. 41, 673-702[CrossRef][Medline] [Order article via Infotrieve]
29. Orlean, P., Kuranda, M. J., and Albright, C. F. (1991) Methods Enzymol. 194, 682-697[Medline] [Order article via Infotrieve]
30. Counillon, L., and Pouyssegur, J. (2000) J. Biol. Chem. 275, 1-4[Free Full Text]
31. Biemesderfer, D., DeGray, B., and Aronson, P. S. (1998) J. Biol. Chem. 273, 12391-12396[Abstract/Free Full Text]
32. Nass, R., and Rao, R. (1999) Microbiology 145, 3221-3228[Abstract/Free Full Text]
33. Wakabayashi, S., Pang, T., Su, X., and Shigekawa, M. (2000) J. Biol. Chem. 275, 7942-7949[Abstract/Free Full Text]
34. Quintero, F. J., Blatt, M. R., and Pardo, J. M. (2000) FEBS Lett. 471, 224-228[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.